SAN DIEGO , March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 4:00 p.m. ET.
NEW YORK , March 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of February 28, 2025, an increase of $2.1 billion from assets under management of $86.4 billion at January 31, 2025. The increase was due to market appreciation of $2.3 billion, partially offset by distributions of $151 million and net outflows of $16 million.
LONDON , March 3, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the launch of the Cohen & Steers SICAV Short Duration Preferred Income Fund. This is the firm's second fund focused on the preferred securities market available to UCITS investors, in addition to the Cohen & Steers SICAV Preferred Income Fund, launched in 2017.
MARLBOROUGH, Mass. , Feb. 25, 2025 /PRNewswire/ -- As part of its strategic expansion in Latin America, Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, is deepening its commitment to the region through new partnerships and customer successes.
Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
Cohen & Steers (CNS) faces AUM declines due to asset depreciation in REITs and preferred shares amid persistent inflation affecting bond markets. This could be a portent for incoming outflows or inflow deceleration. At any rate, the macro changes don't favour long-duration asset ETFs that CNS focuses on. Despite positive net inflows, revenue growth was offset by rising expenses, resulting in flat EPS.
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on February 21, 2025. Cohen & Steers Global Realty Majors Portfolio Index (GRM) Added component (symbol) Removed component (symbol) Hongkong Land Holdings Ltd.
Extending expertise in ERP consulting•implementation•operations across the region Driving client business innovation by integrating AI and cloud advancements into SAP's latest Cloud ERP solutions Delivering differentiated client value through LG CNS solutions such as 'PerfecTwin ERP Edition' and 'SINGLEX' SEOUL, South Korea , Feb. 14, 2025 /PRNewswire/ -- LG CNS today announced that it has joined SAP® Regional Strategic Services Partner (RSSP) initiative, established by SAP Asia Pacific (APAC) to amplify the capabilities and reach of established partners in the APAC region that are on a rapid growth trajectory. Through the RSSP initiative, SAP will provide strategic support to eligible partners, which may include coordinated industry-aligned solutions, joint go-to-market strategy, and access to SAP regional and market unit industry expertise.